Percutaneous Coronary Intervention in Type 2 Diabetic patients
Diabetes mellitus and Cardiovascular diseases are two main chronic disorders that affect a large number of people worldwide.
Type 2 Diabetic Patients have more adverse cardiovascular outcomes after Percutaneous Coronary Intervention (PCI) compared to non-diabetic patients.
However, insulin-treated diabetic patients have even worse clinical outcomes compared to non-insulin treated diabetic patients.
This research has compared the clinical outcomes between insulin treated and non-insulin treated diabetic patients after PCI.
Moreover, type 2 diabetic patients tend to have platelet hyper-reactivity or dysfunction because of which, dual antiplatelet therapy (aspirin and clopidogrel) is not often sufficient after PCI.
This research has also shown how adding cilostazol to this dual antiplatelet therapy (now considered as triple antiplatelet therapy) could benefit these diabetic patients after PCI.
The author, Dr Pravesh Kumar Bundhun, born in the year 1988, is a citizen of Mauritius.
Completed his A-level studies at Royal College Curepipe, one of the top colleges in Mauritius.
Entered the medical field in 2007.
Graduated from Guangxi Medical University in 2012.
Granted a full academic scholarship to complete his Masters Degree (2012-2015).